Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Monday, March 27, 2017
 
Recommended for you
Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report 2017: Focus on Endothelin Receptor Antagonist, Prostacyclin and Prostacyclin, PDE-5 Inhibitors & sGC Stimulator - Research and Markets
BusinessWire
How Health Care Stocks Responded to the Shelved Health Care Bill
24/7 Wall St. • 247chrislange
Marketplace Roundtable: Biotech Hanging In The Balance
Seeking Alpha • S.A. Marketplace
Jerome Dodson And The Parnassus Funds: Why Are They So Successful? It's Simple
Seeking Alpha • Roderick Maciver
The Best-Case Scenario for Gilead Sciences, Inc.
Fool.com: The Motley Fool • Keith Speights
After Trump rally, equity investors move into healthcare, retailers
Reuters • David Randall
After Trump rally, equity investors move into healthcare, retailers
Reuters • David Randall
Hedge Fund Manager Ken Griffin Winds Back on Valeant Pharmaceuticals Intl Inc (VRX) and Apple Inc. (AAPL), Jacks Up Gilead Sciences
Smarter Analyst • Editor, Julie Lamb
My 3 Worst-Performing Stocks -- and Why I Still Own Them
Fool.com: The Motley Fool • Keith Speights
What to Expect from Gilead Sciences, Inc. (GILD) Amid M&A Buzz and Upcoming Catalysts
Smarter Analyst • Editor, Julie Lamb
 
Recommended for You
Actelion Pharmaceuticals, Gilead Sciences
Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report 2017: Focus on Endothelin Receptor Antagonist, Prostacyclin and Prostacyclin, PDE-5 Inhibitors & sGC Stimulator - Research and Markets
BusinessWire
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of...
Share
Gilead Sciences, Health Care Industry
How Health Care Stocks Responded to the Shelved Health Care Bill
24/7 Wall St.247chrislange
Despite touting himself as an incredible dealmaker and negotiater, Trump faced the biggest defeat of his presidency thus far when legislation to repeal the Affordable Care Act was pulled from a vote in the House of Representatives. This had long been a...
Share
Gilead Sciences, Health Finance
Marketplace Roundtable: Biotech Hanging In The Balance
Seeking AlphaS.A. Marketplace
Summary As Capitol Hill swirls around the possibility of a new healthcare bill, biotech investors would do well to keep an eye on developments. But there are other areas of the industry to focus on, whether M&A activity, oncology progress, CRISPR innovations,...
Share
Gilead Sciences
Jerome Dodson And The Parnassus Funds: Why Are They So Successful? It's Simple
Seeking AlphaRoderick Maciver
Summary The Parnassus funds follow simple investment principles. Invest in companies: With exceptional long-term profitability. During periods of temporary adversity, or when the market is negative on the prospects of an entire sector. That are socially responsible, in particular that are good...
Share
Gilead Sciences
The Best-Case Scenario for Gilead Sciences, Inc.
Fool.com: The Motley FoolKeith Speights
Throw in the towel. Cry uncle. Give up. Gilead Sciences (NASDAQ:GILD) is toast. Really? With revenue and earnings falling, the sentiment about Gilead is largely negative these days. However, the biotech's future might be brighter than some think. Here's a best-case scenario...
Share
Gilead Sciences
After Trump rally, equity investors move into healthcare, retailers
ReutersDavid Randall
High U.S. share prices are pushing Lipper Award-winning equity fund managers into the shares of beaten-down healthcare companies, retailers and emerging-market stocks that they say offer a greater chance for outsized gains. Fund managers from Poplar Forest, Parnassus Investments and Brandes Investment...
Share
Gilead Sciences
After Trump rally, equity investors move into healthcare, retailers
ReutersDavid Randall
High U.S. share prices are pushing Lipper Award-winning equity fund managers into the shares of beaten-down healthcare companies, retailers and emerging-market stocks that they say offer a greater chance for outsized gains. Fund managers from Poplar Forest, Parnassus Investments and Brandes Investment...
Share
Apple Inc, Biotechnology
Hedge Fund Manager Ken Griffin Winds Back on Valeant Pharmaceuticals Intl Inc (VRX) and Apple Inc. (AAPL), Jacks Up Gilead Sciences
Smarter AnalystEditor, Julie Lamb
Hedge fund founder of Citadel Ken Griffin did not stake his claim as the wealthiest man in Illinois, by Forbes’ reckoning, without playing it smart. Having once asserted, “Every organization has two choices. Choice one is to grow. Choice two is to...
Share
Gilead Sciences
My 3 Worst-Performing Stocks -- and Why I Still Own Them
Fool.com: The Motley FoolKeith Speights
I own 20 stocks in my investing portfolio, plus a handful of exchange-traded funds (ETFs). Most of these stocks and ETFs have performed quite well over the past 12 months. But not all of them. Three of the stocks that I own...
Share
Gilead Sciences
What to Expect from Gilead Sciences, Inc. (GILD) Amid M&A Buzz and Upcoming Catalysts
Smarter AnalystEditor, Julie Lamb
Analysts see an interesting path ahead for Gilead Sciences, Inc. (NASDAQ:GILD), between exciting collaborative possibilities and its pipeline catalysts that have brought bullish notes across the board to the surface. However, even with confidence, there is clearly rising pressure for Gilead to...
Share